Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.

Thiel, Uwe; Wawer, Angela; von Luettichau, Irene; Bender, Hans-Ulrich; Blaeschke, Franziska; Grünewald, Thomas G P; Steinborn, Marc; Röper, Barbara; Bonig, Halvard; Klingebiel, Thomas; Bader, Peter; Koscielniak, Ewa; Paulussen, Michael; Dirksen, Uta; Juergens, Heribert; Kolb, Hans-Jochem; Burdach, Stefan E G

doi:10.18632/oncotarget.10938

2016

Back
Back to start of result list
Permanent link for displayed object

Title:: Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.
Document type:: Journal Article; Article
Author(s):: Thiel, Uwe; Wawer, Angela; von Luettichau, Irene; Bender, Hans-Ulrich; Blaeschke, Franziska; Grünewald, Thomas G P; Steinborn, Marc; Röper, Barbara; Bonig, Halvard; Klingebiel, Thomas; Bader, Peter; Koscielniak, Ewa; Paulussen, Michael; Dirksen, Uta; Juergens, Heribert; Kolb, Hans-Jochem; Burdach, Stefan E G
Abstract:: Advanced Ewing sarcomas have poor prognosis. They are defined by early relapse (<24 months after diagnosis) and/or by metastasis to multiple bones or bone marrow (BM). We analyzed risk factors, toxicity and survival in advanced Ewing sarcoma patients treated with the MetaEICESS vs. EICESS92 protocols.Of 44 patients, 18 patients were enrolled into two subsequent MetaEICESS protocols between 1992 and 2014, and compared to outcomes of 26 advanced Ewing sarcoma patients treated with EICESS 1992 between 1992 and 1996. MetaEICESS 1992 consisted of induction chemotherapy, whole body imaging directed radiotherapy to the primary tumor and metastases, tandem high-dose chemotherapy and autologous rescue. In MetaEICESS 2007 this treatment was complemented by allogeneic stem cell transplantation. EICESS 1992 comprised induction chemotherapy, local therapy to the primary tumor only followed by consolidation chemotherapy.In MetaEICESS 8/18 patients survived in complete remission vs. 2/26 in EICESS 1992 (p<0.05). Survival did not differ between MetaEICESS 2007 and MetaEICESS 1992. Three MetaEICESS patients died of complications, all in MetaEICESS 1992. After exclusion of patients succumbing to treatment related complications (n=3), 7/10 patients survived without BM involvement, in contrast to 0/5 patients with BM involvement. This was confirmed in a multivariate analysis. There was no correlation between BM involvement and the number of metastases at diagnosis.The MetaEICESS protocols yield long-term disease-free survival in patients with advanced Ewing sarcoma. Allogeneic stem cell transplantation was not associated with increased death of complications. Bone marrow involvement is a risk factor distinct from multiple bone metastases.
Journal title abbreviation:: Oncotarget
Year:: 2016
Journal volume:: 7
Journal issue:: 43
Pages contribution:: 70959-70968
Language:: eng
Fulltext / DOI:: doi:10.18632/oncotarget.10938
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/27486822
TUM Institution:: Klinik und Poliklinik für Kinderheilkunde und Jugendmedizin; Klinik und Poliklinik für RadioOnkologie und Strahlentherapie
BibTeX

Occurrences:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für RadioOnkologie und Strahlentherapie (Prof. Combs)2016

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für Kinder- und Jugendmedizin (Prof. Hauer)2016